Displaying drugs 15026 - 15050 of 15406 in total
HH-009
HH-009 is a recombinant human IgG4 monoclonal antibody against FGF19 being studied for the treatment of hepatocellular carcinoma.
Investigational
HTPEP-001
HTPEP-001 is a novel peptide that works to inhibit the activation of transforming growth factor beta (TGF-β). It is being investigated for the treatment of fibrosis.
Investigational
Sacituzumab tirumotecan
Sacituzumab tirumotecan is a recombinant humanized IgG1 anti-TROP2 monoclonal antibody conjugated to a topoisomerase I inhibitor.
Investigational
Sasanlimab
Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).
Investigational
Ragifilimab
Ragifilimab is under investigation in clinical trial NCT04225039 (Anti-gitr/anti-pd1/stereotactic Radiosurgery, in Recurrent Glioblastoma).
Investigational
SGN-B6A
Sigvotatug vedotin (SGN-B6A) is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
Volrustomig
Volrustomig is under investigation in clinical trial NCT06097728 (MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma).
Investigational
Lacripep
Lacripep is under investigation in clinical trial NCT03226444 (Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome).
Investigational
Acasunlimab
Acasunlimab is under investigation in clinical trial NCT06046274 (GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer).
Investigational
Petosemtamab
Petosemtamab is under investigation in clinical trial NCT03526835 (A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors).
Investigational
Vilamakitug
Vilamakitug is under investigation in clinical trial NCT05201352 (Evaluation of Efficacy of Trifluridine/tipiracil Plus an Anti-il-1α True Human Antibody Versus Trifluridine/tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine).
Investigational
Tobevibart
Tobevibart is under investigation in clinical trial NCT05612581 (A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection).
Investigational
Survodutide
Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)).
Investigational
Rezpegaldesleukin
Rezpegaldesleukin is under investigation in clinical trial NCT04433585 (A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)).
Investigational
L-756423
Experimental
Matched Iupac: … (2S)-4-[(1-benzofuran-2-yl)methyl]-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(2R)-2-hydroxy-2,3-dihydro-1H-inden …
9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE
Experimental
Matched Iupac: … hydroxymethyl)-6-{4-oxo-1H,4H,5H-pyrrolo[3,2-d]pyrimidin-7-yl}-tetrahydro-2H-furo[3,4-d][1,3]dioxol-2-yl]methyl …
Quingestanol acetate
Experimental
Matched Iupac: … (1R,3aS,3bR,9aR,9bS,11aS)-7-(cyclopentyloxy)-1-ethynyl-11a-methyl-1H,2H,3H,3aH,3bH,4H,8H,9H,9aH,9bH,10H …
LY-2623091
LY-2623091 is under investigation in clinical trial NCT02194465 (A Study of LY2623091 in Participants With High Blood Pressure).
Investigational
Matched Iupac: … (5-{[(2E)-6-fluoro-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene]methyl}-1 …
Vapitadine
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … is developing as a treatment for allergic reactions of the skin, such as those associated with hives and …
MK-0354
MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.
Investigational
Matched Description: … orally administered drug candidate under development by Merck for the treatment of atherosclerosis and …
Displaying drugs 15026 - 15050 of 15406 in total